Table 2.

Experimental groups.

Group	Vaccine/adjuvant	Drug
Infected Untreated	None	None
Low dose E6020	5 µg E6020 SE	None
High dose E6020	25 µg E6020 SE	None
Low dose BZN	None	25 mg/kg orally for 7 days
High dose BZN (curative)	None	100 mg/kg orally for 7 days
Low dose vaccine	25 µg Tc24-C4 + 5 µg E6020 SE	None
High dose vaccine	100 µg Tc24-C4 + 25 µg E6020 SE	None
Low dose vaccine + BZN	25 µg Tc24-C4 + 5 µg E6020 SE	25 mg/kg orally for 7 days
High dose vaccine + BZN	100 µg Tc24-C4 + 25 µg E6020 SE	25 mg/kg orally for 7 days

All mice were infected with 500 T. cruzi H1 by intraperitoneal injection. Treated mice were prime-immunized subcutaneously on day 7 and boosted at day 14 post-infection. BZN was administered by oral administration once daily beginning 7 days post-infection.